Updated cost comparison of home care subcutaneous versus outpatient intravenous trastuzumab for HER2-positive breast cancer in Singapore
Therapeutic Advances in Medical Oncology · 2026-03 · 18
DOI: 10.1177/17588359261421557 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 25.03.2026. Verfasst von Yanting Ouyang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Health Services Research & Population Health, Duke-NUS Medical School, Singapore, Singapore. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Ambulante Pflege
Abstract (Originalsprache)
Background
With major changes in effective drug prices, we updated our earlier cost-minimization analysis comparing home-based subcutaneous (SC) trastuzumab with outpatient intravenous (IV) trastuzumab for HER2-positive breast cancer in Singapore.
Objectives
To compare updated annual per-patient costs of home care SC versus outpatient IV trastuzumab.
Design
A cost-minimization analysis was performed.
Methods
We conducted a model-based cost-minimization analysis using micro-costing from a societal perspective, incorporating both direct and indirect costs. A Monte Carlo simulation was performed to account for parameter uncertainties.
Results
Annual per-patient cost was S$21,790 (95% uncertainty interval (UI): S$19,662–23,922) for home care versus S$6949 (95% UI: S$5347–10,782) for outpatient care, representing a 214% increase. While service delivery (manpower, facility, consumables) and productivity loss remained cheaper in home care, drug cost is the dominant factor of overall expenditure in trastuzumab delivery.
Conclusion
At current drug prices, outpatient IV trastuzumab administration is the cost-saving option, compared with home care SC trastuzumab.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Health Services Research & Population Health, Duke-NUS Medical School, Singapore, Singapore.
- Office for Service Transformation, SingHealth, Singapore, Singapore.
- Health Services Research & Population Health, Duke-NUS Medical School, Singapore 168582, Singapore.
ORCID-Profile: Yanting Ouyang
Zitieren
APA
Ouyang, Y., Ng, Y. T., Hong, W. W., & Graves, N. (2026). Updated cost comparison of home care subcutaneous versus outpatient intravenous trastuzumab for HER2-positive breast cancer in Singapore. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261421557
Vancouver
Ouyang Y, Ng YT, Hong WW, Graves N. Updated cost comparison of home care subcutaneous versus outpatient intravenous trastuzumab for HER2-positive breast cancer in Singapore. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261421557
BibTeX
@article{Ouyang2026,
author = {Ouyang, Yanting and Ng, Yi Ting and Hong, Wei Wei and Graves, Nicholas},
title = {Updated cost comparison of home care subcutaneous versus outpatient intravenous trastuzumab for HER2-positive breast cancer in Singapore},
journal = {Therapeutic Advances in Medical Oncology},
year = {2026},
volume = {18},
doi = {10.1177/17588359261421557}
}
EUVIMED